中国神经再生研究(英文版) ›› 2022, Vol. 17 ›› Issue (10): 2213-2214.doi: 10.4103/1673-5374.335794

• 观点:脑损伤修复保护与再生 • 上一篇    下一篇

脑源性无细胞DNA

  

  • 出版日期:2022-10-15 发布日期:2022-03-16

Brain-derived cell-free DNA

Dean Southwood, Sanyukta Singh, Zac Chatterton   

  1. Brain and Mind Center, School of Medical Sciences, Department of Neuroscience, The University of Sydney, Camperdown, NSW, Australia
  • Online:2022-10-15 Published:2022-03-16
  • Contact: Zac Chatterton, PhD, zac.chatterton@sydney.edu.au.
  • Supported by:
    ZC is generously funded by The University of Sydney Postdoctoral Fellowship. ZC and DS are generously funded by a National Health and Medical Research Council (NHMRC)-European Union Joint Program on Neurodegenerative Disease Research Grant (JPND2019-466-261 & APP11912407).

摘要: https://orcid.org/0000-0002-6683-1400 (Zac Chatterton)

Abstract: Following cell death, DNA can be released into the blood plasma and other body fluids in the form of cell-free DNA (cfDNA). These DNA fragments are typically ~167 bp in length, corresponding to the length of DNA wrapped around one nucleosome core (147 bp), plus DNA tails that survive endogenous DNase digestion (~10 bp). CfDNA is derived from a variety of sources, each having unique diagnostic applications. During pregnancy, fetal-derived cfDNA within an expectant mother’s blood plasma can diagnose fetal genetic abnormalities and is a well-established method for non-invasive prenatal testing. Cancer-derived cfDNA is also detectable within blood plasma by high sensitivity methods (e.g., NGS, ddPCR) and can accurately diagnose cancers by a minimally invasive blood test (Diehl et al., 2008). The short half-life of cfDNA (< 2 hours) also facilitates real-time measurement of disease burden, such as monitoring cancer relapse. There is now growing evidence of brain-derived cfDNA (bd-cfDNA) within the cerebrospinal fluid (CSF) and blood plasma. In this perspective, we review the present understanding, current challenges, and potential utility of bd-cfDNA.